Lung cancer patients lacking MSH2 DNA repair protein fare better with chemo

Therapeutic vaccine improves response rate and extends progression-free survival in patients with metastatic melanoma

Targeting death receptors in chemo-resistant cancer cells

Treatment based on rising CA125 blood levels does not improve survival for recurrent ovarian cancer

Sentinel node biopsy is effective, less invasive option for early-stage cervical cancer patients

Standard treatment plus trastuzumab for HER2+ gastric cancer

Olaparib induces tumour response as single agent in BRCA-deficient breast cancer

PARP inhibitor BS-201 plus chemotherapy: new option for triple-negative breast cancer

Therapeutic cancer vaccine significantly prolongs disease-free survival for follicular lymphoma

Bortezomib based therapies for myeloma

Zoledronic acid for treament of prostate cancer

Cancer prevention strategies

PSA/Prostate screening

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

PARP inhibitors show promise for hard-to-treat breast cancers

ASCO: Patient accrual in clinical trials

ASCO: Prophylactic creams and antibiotics reduce severe drug-related skin rash

ASCO: Impact of common antidepressants on tamoxifen effectiveness

ASCO: Pemetrexed extends survival as maintenance therapy

ASCO: Oxaliplatin does not improve outcomes for rectal cancer

ASCO: Trial compares common adjuvant treatments for pancreatic cancer

ASCO: Surgery unnecessary for majority of patients with advanced colorectal cancer

ASCO: Lung cancer screening by low-dose computed tomography results in high rate of false positives

ASCO: Low rates of screening among childhood cancer survivors

ASCO: Childhood cancer survivors at risk of post-traumatic stress disorder

ASCO: Maintenance therapy for NSCLC

Oestrogen and progestin therapy increases NSCLC risk

ASCO: Experimental targeted therapy improves progression-free survival for advanced NSCLC

ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer

Results of the new Cetuximab studies in mCRC, from ASCO 2008

Cetuximab and docetaxal for squamous cell cancer of the head and neck, from ASCO 2008

Cetuximab for NSCLC, from ASCO 2008

Cetuximab for NSCLC, from ASCO 2008

Cetuximab for metastatic colorectal cancer (mCRC), from ASCO 2008